<DOC>
	<DOCNO>NCT00762749</DOCNO>
	<brief_summary>To characterize pharmacokinetics diphenhydramine two pediatric population : child , age 2 &lt; 12 year , adolescent , age 12 &lt; 18 year .</brief_summary>
	<brief_title>Study Evaluate Diphenhydramine Children Adolescents</brief_title>
	<detailed_description>This study open-label , single-dose classical pharmacokinetic design comparator treatment group . Twenty-four ( 24 ) child , age 2 &lt; 12 year , 12 adolescent , age 12 &lt; 18 year , symptom due hay fever upper respiratory allergy complete study . To ensure young child represent , least 35 % ( 8 ) child enrol range 2 &lt; 6 year age .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Diphenhydramine</mesh_term>
	<mesh_term>Promethazine</mesh_term>
	<criteria>Male female child adolescent , age 2 &lt; 18 year , minimum weight 24 pound eligible participate . In addition , subject &gt; 5th percentile &lt; 95th percentile weight base age gender . Subjects body mass index ( BMI ) &gt; 5th percentile less equal 90th percentile age gender . Subjects history allergic rhinitis experience symptom due hay fever upper respiratory allergy include . Subjects use concurrent medication , except lowdose inhaled glucocorticosteroids allergic rhinitis mild concurrent asthma , dose stabilize entry study ( ie , dose change 1 month prior entry study ) , inhale shortacting beta2 adrenergic agonist concomitant asthma , need ; Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic disease . Findings medical history physical examination vital sign measurement within range clinical acceptability . Have know sensitivity allergy diphenhydramine EMLA cream . Have know sensitivity allergy red dye . Have asthma symptom time study entry require medication allow Inclusion Criterion 4 ; Took prescription ( allow Inclusion Criterion 4 ) nonprescription medication , within seven day five halflives ( whichever longer ) study 's start date . Took herbal supplement drink grapefruit juice 28 day study 's start date . Participated , complete , another clinical trial within seven week study 's start date . Have history drug , alcohol , tobacco use ( old child adolescent ) Have history hepatitis B , previous positive test hepatitis B surface antigen , previous positive hepatitis C antibody . Have history HIV infection previous demonstration HIV antibody . Pregnant nursing female ; female childbearing potential unwilling unable use acceptable method contraception least three month prior first dose study medication completion followup procedure .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>